Immunic, inc. announces pricing of $45 million public offering of common stock

New york, july 15, 2021 /prnewswire/ -- immunic, inc. (the "company") (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $10 per share. the gross proceeds of the offering to the company are expected to be approximately $45 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
IMUX Ratings Summary
IMUX Quant Ranking